This inventor holds 2 USPTO granted patents. Top assignee: Daewoong Pharmaceutical Co., Ltd.. Active years: 2016-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016-2017
Title: Eun-Ji Koh: Innovator in Pharmaceutical Composition
Introduction
Eun-Ji Koh is a prominent inventor based in Gyeonggi-do, South Korea. She has made significant contributions to the field of pharmaceuticals, particularly in the treatment of hyperlipidemia and hypertriglyceridemia. With a total of 2 patents to her name, her work is paving the way for innovative solutions in healthcare.
Latest Patents
Eun-Ji Koh's latest patents include a pharmaceutical composition for preventing or treating hyperlipidemia. This composition comprises (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one or its pharmaceutically acceptable salt, along with an angiotensin II receptor blocker as active ingredients. Another notable patent is a method for treating hypertriglyceridemia, which includes the same compound in combination with amlodipine or its pharmaceutically acceptable salt at a synergistic ratio of about 4:1.
Career Highlights
Eun-Ji Koh is currently employed at Daewoong Pharmaceutical Co., Ltd., where she continues to innovate and develop new pharmaceutical solutions. Her work has garnered attention in the industry, contributing to advancements in the treatment of lipid-related conditions.
Collaborations
Eun-Ji Koh collaborates with esteemed colleagues, including Jong-Wook Lee and Sang-Ho Lee. Their combined expertise enhances the research and development efforts at Daewoong Pharmaceutical Co., Ltd.
Conclusion
Eun-Ji Koh is a trailblazer in the pharmaceutical industry, with her innovative patents addressing critical health issues. Her contributions are vital in the ongoing fight against hyperlipidemia and related diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
